

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Jun INOUE et al. :
Serial No. NEW : **Attn: APPLICATION BRANCH**
Filed June 26, 2003 : Attorney Docket No. 2003_0731

**PROPHYLACTIC OR THERAPEUTIC COMPOSITION
FOR OCULAR CIRCULATION DISORDERS
(Rule 1.53(b) Divisional of Serial No. 09/762,401,
Filed February 7, 2001)**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of ☒ the references listed on attached form PTO-1449 and/or ☐ the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No. 09/762,401.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page ,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Jun INOUE et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 26, 2003

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: June 26, 2003

ATTY DOCKET NO.
2003_0731SERIAL NO.
NEWAPPLICANT
Jun INOUE et al.FILING DATE
June 26, 2003

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,306,824	4/94				
	AB	5,314,815	5/94				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AC	93/15732	8/93	WO				
	AD	8-67674	3/96	JP				
	AE	92/10183	6/92	WO				
	AF	92/10179	6/92	WO				
	AG	93/25574	12/93	WO				
	AH	96/4248	2/96	WO				
	AI	97/11941	4/97	WO				
	AJ	713876	5/96	EP				
	AK	96/33974	10/96	WO				
	AL	98/9949	3/98	WO				
	AM	98/18794	5/98	WO				
	AN	9-31061	2/97	JP				
	AO	10-87567	4/98	JP				
	AP	9-124691	5/97	JP				
	AQ	10-7661	1/98	JP				
	AR	10-53579	2/98	JP				

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AS	
--	----	--

EXAMINER

DATE CONSIDERED

Sheet 2 of 2							
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE , PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: June 26, 2003				ATTY DOCKET NO. 2003_0731		SERIAL NO. NEW	
				APPLICANT Jun INOUE et al.			
				FILING DATE June 26, 2003		GROUP	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,639,773	6/1997	Kubo et al.	514	382	
	BB	5,814,631	9/1998	Fukami et al.	514	234.5	
	BC	6,080,738	6/2000	Akahoshi et al.	514	227.8	
	BD	6,271,238	8/2001	Suzuki et al.	514	269	
	BE	5,948,785	9/1999	Akahoshi et al.	514	269	
	BF	5,691,335	11/1997	Fukami et al.	514	235.8	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BG						Corresponds to Ref BA
	BH						
	BI						
	BJ						
	BK						
	BL						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BM	H. Okunishi et al., "Evidence for a Putatively New Angiotensin II-Generating Enzyme in the Vascular Wall", Journal of Hypertension, Vol. 2, No. 3, 1984, pp.277-284.					
EXAMINER				DATE CONSIDERED			

**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*